FOCUS-How GSK plans to replenish its depleted medicine cabinet
GSK's chief scientist says an overhaul of the drugmaker's R&D unit has begun delivering results - citing an RSV vaccine and promising hepatitis B and asthma treatments - and pledged a tighter focus than his predecessor on infectious disease and HIV.
GSK's chief scientist says an overhaul of the drugmaker's R&D unit has begun delivering results - citing an RSV vaccine and promising hepatitis B and asthma treatments - and pledged a tighter focus than his predecessor on infectious disease and HIV.
